Indexed keywords
NEW DRUG;
BIOTECHNOLOGICAL PRODUCTION;
COST;
COST MINIMIZATION ANALYSIS;
DRUG INDUSTRY;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
KNOWLEDGE;
MODEL;
PRODUCTIVITY;
REVIEW;
TAX;
VIRTUAL REALITY;
HUMAN;
ORGANIZATION AND MANAGEMENT;
RESEARCH;
THEORETICAL MODEL;
TRANSLATIONAL RESEARCH;
TRENDS;
DRUG INDUSTRY;
EFFICIENCY, ORGANIZATIONAL;
HUMANS;
KNOWLEDGE;
MODELS, THEORETICAL;
RESEARCH;
TRANSLATIONAL MEDICAL RESEARCH;
1
77949435336
European Commission Joint Research Centre, Directorate General Research European Commission
European Commission Joint Research Centre, Directorate General Research The 2012 EU Industrial R&D Investment Scoreboard 2012 European Commission
(2012)
The 2012 EU Industrial R&D Investment Scoreboard
2
84859634432
Pharmaceutical Research and Manufacturers of America (PhRMA) PhRMA
Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceutical Industry 2011 Profile 2011 PhRMA
(2011)
Pharmaceutical Industry 2011 Profile
3
84867593328
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) IFPMA
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) The Pharmaceutical Industry and Global Health: Facts and Figures 2011 IFPMA
(2011)
The Pharmaceutical Industry and Global Health: Facts and Figures
4
77649234756
How to improve R&D productivity: The pharmaceutical industry's grand challenge
S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
(2010)
Nat. Rev. Drug Discov. , vol.9
, pp. 203-214
Paul, S.M.1
5
77149134011
Deconstructing the drug development process: The new face of innovation
K.I. Kaitin Deconstructing the drug development process: the new face of innovation Clin. Pharmacol. Ther. 87 2010 356 361
(2010)
Clin. Pharmacol. Ther. , vol.87
, pp. 356-361
Kaitin, K.I.1
6
73449101512
Lessons from 60 years of pharmaceutical innovation
B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
(2009)
Nat. Rev. Drug Discov. , vol.8
, pp. 959-968
Munos, B.1
7
4344645978
Can the pharmaceutical industry reduce attrition rates?
I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 716
(2004)
Nat. Rev. Drug Discov. , vol.3
, pp. 711-716
Kola, I.1
Landis, J.2
8
12144268237
Macro trends in pharmaceutical innovation
F.J. Cohen Macro trends in pharmaceutical innovation Nat. Rev. Drug Discov. 4 2005 78 84
(2005)
Nat. Rev. Drug Discov. , vol.4
, pp. 78-84
Cohen, F.J.1
9
78951480503
Pharmaceutical Innovation in the 21st century: New drug approvals in the first decade, 2000-2009
K.I. Kaitin, and J.A. DiMasi Pharmaceutical Innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin. Pharmacol. Ther. 89 2010 183 188
(2010)
Clin. Pharmacol. Ther. , vol.89
, pp. 183-188
Kaitin, K.I.1
Dimasi, J.A.2
10
79960982560
The impact of mergers on pharmaceutical R&D
J.L. LaMattina The impact of mergers on pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 559 560
(2011)
Nat. Rev. Drug Discov. , vol.10
, pp. 559-560
Lamattina, J.L.1
11
59349115917
2008 FDA drug approvals
B. Hughes 2008 FDA drug approvals Nat. Rev. Drug Discov. 8 2009 93 96
(2009)
Nat. Rev. Drug Discov. , vol.8
, pp. 93-96
Hughes, B.1
12
84856509534
2011 FDA drug approvals
A. Mullard 2011 FDA drug approvals Nat. Rev. Drug Discov. 11 2012 91 94
(2012)
Nat. Rev. Drug Discov. , vol.11
, pp. 91-94
Mullard, A.1
14
75949093281
Is open innovation the way forward for big pharma?
J. Hunter, and S. Stephens Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9 2010 87 88
(2010)
Nat. Rev. Drug Discov. , vol.9
, pp. 87-88
Hunter, J.1
Stephens, S.2
